Ccf-mtDNA as a potential biomarker for assessing treatment response and relapse in plaque psoriasis during Xeligekimab therapy (EADV 2026) - Aug 6, 2026 - Abstract #P1189; AS-1636; Pres time: Sep 30, 2026; Location: ePoster Area; "These findings suggest that ccf-mtDNA may reflect inflammatory disease activity and may serve as a potential biomarker for therapeutic monitoring and relapse detection. Larger studies are needed to validate these preliminary observations"
Biomarker • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis • IL17A
|
|
Bingxue Bai 1; Iuliia Kadyrova 1; Caiyu Xie 1
|